I am a physician (currently practicing Child Psychiatry, also board certified in Pediatrics) and part-time investor. I invest in several biotech companies, including Dynavax Technologies (NASDAQ:DVAX), the main subject of this article. I look for the combination of good science, depth of pipeline, a market cap that appears undervalued, and a reasonably good technical stock profile. While Dynavax may have some concerns with regards to depth of pipeline and technical indicators, I believe that Dynavax represent an incredible value due to the near-certainty of HEPLISAV-B and the unrecognized potential of AZD1419.
On August 7th, 2014, Dynavax released Quarterly Results that included four main items. These were financial updates and an update on each of the...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|
|PRO Top long ideas returned 21.7% in 2016**|